Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?

Clinical Colorectal Cancer

Volumn 17, Issue 1, 2018, Pages e109-e113

  Ibrahim, Sajida ^a   Girault, Alban ^a   Ohresser, Marc ^a   Lereclus, Emilie ^a   Paintaud, Gilles ^a,b   Lecomte, Thierry ^a,b   Raoul, William ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Interleukin 17; Mechanisms of resistance; Monoclonal antibodies; Polymorphisms; Vascular endothelial growth factor

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; IL17A PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; GENETIC POLYMORPHISM; HUMAN; METASTATIC COLORECTAL CANCER; NONHUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; DRUG RESISTANCE; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-17; RECEPTORS, INTERLEUKIN-17; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85033771220     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2017.10.003     Document Type: Review

References (67)

1. Bossard, N., Velten, M., Remontet, L., et al. Survival of cancer patients in France: a population-based study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43 (2007), 149–160.
2. Jooste, V., Remontet, L., Colonna, M., et al. Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. Eur J Cancer Prev 20 (2011), 375–380.
3. Favoriti, P., Carbone, G., Greco, M., Pirozzi, F., Pirozzi, R.E., Corcione, F., Worldwide burden of colorectal cancer: a review. Updates Surg 68 (2016), 7–11.
4. Sanz-Garcia, E., Grasselli, J., Argiles, G., Elez, M.E., Tabernero, J., Current and advancing treatments for metastatic colorectal cancer. Expert Opin Biol Ther 16 (2016), 93–110.
5. Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997), 404–407.
6. Kieran, M.W., Kalluri, R., Cho, Y.J., The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med, 2, 2012, a006593.
7. Mirone, G., Shukla, A., Marfe, G., Signaling mechanisms of resistance to EGFR- and anti-angiogenic inhibitors cancer. Crit Rev Oncol Hematol 97 (2016), 85–95.
8. Tejpar, S., Prenen, H., Mazzone, M., Overcoming resistance to antiangiogenic therapies. Oncologist 17 (2012), 1039–1050.
9. Fan, F., Samuel, S., Gaur, P., et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104 (2011), 1270–1277.
10. Yamagishi, N., Teshima-Kondo, S., Masuda, K., et al. Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer, 13, 2013, 229.
11. Mésange, P., Poindessous, V., Sabbah, M., Escargueil, A.E., de Gramont, A., Larsen, A.K., Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small-molecule angiokinase inhibitor. Oncotarget 5 (2014), 4709–4721.
12. Gaffen, S.L., Jain, R., Garg, A.V., Cua, D.J., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14 (2014), 585–600.
13. Ouyang, W., Kolls, J.K., Zheng, Y., The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008), 454–467.
14. Steinman, L., A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007), 139–145.
15. Yang, B., Kang, H., Fung, A., Zhao, H., Wang, T., Ma, D., The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm, 2014, 2014, 623759.
16. Zou, W., Restifo, N.P., T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10 (2010), 248–256.
17. Miossec, P., Kolls, J.K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11 (2012), 763–776.
18. Murugaiyan, G., Saha, B., Protumor vs antitumor functions of IL-17. J Immunol 183 (2009), 4169–4175.
19. Iwakura, Y., Ishigame, H., Saijo, S., Nakae, S., Functional specialization of interleukin-17 family members. Immunity 34 (2011), 149–162.
20. Hirota, K., Ahlfors, H., Duarte, J.H., Stockinger, B., Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep 13 (2011), 113–120.
21. Chang, S.H., Dong, C., IL-17F: regulation, signaling and function in inflammation. Cytokine 46 (2009), 7–11.
22. Le Gouvello, S., Bastuji-Garin, S., Aloulou, N., et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57 (2008), 772–779.
23. Georgiades, I.B., Curtis, L.J., Morris, R.M., Bird, C.C., Wyllie, A.H., Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 18 (2000), 7933–7940.
24. Tang, R., Changchien, C.R., Wu, M.C., et al. Colorectal cancer without high microsatellite instability and chromosomal instability–an alternative genetic pathway to human colorectal cancer. Carcinogenesis 25 (2003), 841–846.
25. Cui, G.L., Yuan, A.P., Goll, R., Florholmen, J., IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand J Gastroenterol 47 (2012), 1304–1312.
26. Liu, J., Duan, Y., Cheng, X., et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407 (2011), 348–354.
27. Radosavljevic, G., Ljujic, B., Jovanovic, I., et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57 (2010), 135–144.
28. Wang, J., Xu, K., Wu, J., et al. The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer, 12, 2012, 418.
29. Lereclus, E., Tout, M., Girault, A., et al. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer, 17, 2017, 220.
30. Tosolini, M., Kirilovsky, A., Mlecnik, B., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 71 (2011), 1263–1271.
31. Housseau, F., Wu, S., Wick, E.C., et al. Microenvironment and immunology redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res 76 (2016), 2115–2124.
32. Tseng, J.Y., Yang, C.Y., Liang, S.C., et al. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res 20 (2014), 2885–2897.
33. Wang, K., Kim, M.K., Di Caro, G., et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41 (2014), 1052–1063.
34. Chung, A.S., Wu, X.M., Zhuang, G.L., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19 (2013), 1114–1123.
35. Zhao, Y., Wu, T., Shao, S., Shi, B., Zhao, Y., Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology, 5, 2016, e1004983.
36. Manjili, M.H., Wang, X.Y., Abrams, S., Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs. Front Immunol, 5, 2014, 303.
37. Obermajer, N., Wong, J.L., Edwards, R.P., et al. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 210 (2013), 1433–1445.
38. Xie, Z., Qu, Y., Leng, Y., et al. Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses. Drug Des Devel Ther 9 (2015), 1679–1689.
39. Wang, L., Yi, T., Kortylewski, M., Pardoll, D.M., Zeng, D., Yu, H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206 (2009), 1457–1464.
40. Numasaki, M., Fukushi, J., Ono, M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003), 2620–2627.
41. Do Thi, V.A., Park, S.M., Lee, H., et al. The membrane-bound form of IL-17A promotes the growth and tumorigenicity of colon cancer. Mol Cells 39 (2016), 536–542.
42. Chen, J., Xia, J., Liang, X., et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 7 (2011), 53–60.
43. Kryczek, I., Wei, S., Szeliga, W., Vatan, L., Zou, W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114 (2009), 357–359.
44. Qian, X., Chen, H., Wu, X., Hu, L., Huang, Q., Jin, Y., Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 89 (2017), 34–44.
45. De Simone, V., Pallone, F., Monteleone, G., Stolfi, C., Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology, 2, 2013, e26617.
46. Tong, Z., Yang, X.O., Yan, H., et al. A protective role by interleukin-17F in colon tumorigenesis. Katoh M, ed PLoS One, 7, 2012, e34959.
47. Ye, J., Livergood, R.S., Peng, G., The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182 (2013), 10–20.
48. McGovern, D.P., Rotter, J.I., Mei, L., et al. Genetic epistasis of IL23/IL17 pathway genes in Crohn disease. Inflamm Bowel Dis 15 (2009), 883–889.
49. Hayashi, R., Tahara, T., Shiroeda, H., et al. Influence of IL17A polymorphisms (rs2275913 and rs3748067) on the susceptibility to ulcerative colitis. Clin Exp Med 13 (2013), 239–244.
50. Eaden, J.A., Abrams, K.R., Mayberry, J.F., The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001), 526–535.
51. Liu, X.K., Lin, X., Gaffen, S.L., Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem 279 (2004), 52762–52771.
52. Kawaguchi, M., Takahashi, D., Hizawa, N., et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 117 (2006), 795–801.
53. Duan, Y., Shi, J.N., Pan, C., Chen, H.L., Zhang, S.Z., Association between the interleukin-17A -197G>A (rs2275913) polymorphism and risk of digestive cancer. Asian Pac J Cancer Prev 15 (2014), 9295–9300.
54. Rafiei, A., Hosseini, V., Janbabai, G., et al. Polymorphism in the interleukin-17A promoter contributes to gastric cancer. World J Gastroenterol 19 (2013), 5693–5699.
55. Wu, X., Zeng, Z., Chen, B., et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer 127 (2010), 86–92.
56. Zhang, X.X., Zheng, L., Sun, Y., Zhang, X.X., Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population. Tumour Biol 35 (2014), 1575–1580.
57. Dai, Z.M., Zhang, T.S., Lin, S., et al. Role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in risk of cancer development: an updated meta-analysis. Sci Rep, 6, 2016, 20439.
58. Nemati, K., Golmoghaddam, H., Hosseini, S.V., Ghaderi, A., Doroudchi, M., Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression. Gene 561 (2015), 88–94.
59. Omrane, I., Marrakchi, R., Baroudi, O., et al. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol 35 (2014), 6627–6632.
60. Lu, Y., Gu, J., Lu, H., et al. Association between IL-17A +197 G/A polymorphism and cancer risk: a meta-analysis. Genet Test Mol Biomarkers 20 (2016), 24–30.
61. Lowes, M.A., Bowcock, A.M., Krueger, J.G., Pathogenesis and therapy of psoriasis. Nature 445 (2007), 866–873.
62. Chao, C.C., Chen, S.J., Adamopoulos, I.E., et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44 (2011), 243–252.
63. Hueber, W., Patel, D.D., Dryja, T., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med, 2, 2010, 52ra72.
64. Gordon, K.B., Blauvelt, A., Papp, K.A., et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375 (2016), 345–356.
65. Lebwohl, M., Strober, B., Menter, A., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
66. Prabhala, R.H., Fulciniti, M., Pelluru, D., et al. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma HHS public access. Leukemia 30 (2016), 379–389.
67. Ma, Y.F., Chen, C., Li, D., et al. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget 8 (2017), 7614–7624.